Buy Venlafaxine online, Buy Effexor online.

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin-norepinephrine reuptake inhibitor class.

It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social phobia. It may also be used for chronic pain.

Therapeutic Class

Serotonin-norepinephrine reuptake inhibitor (SNRI)

Pharmacology

The exact mechanism of action of venlafaxine/Effexor is unknown but appears to be associated with the its potentiation of neurotransmitter activity in the CNS. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), inhibit the reuptake of both serotonin and norepinephrine with a

potency greater for the 5-HT than for the NE reuptake process. Both venlafaxine/Effexor and the ODV metabolite have weak inhibitory effects on the reuptake of dopamine but, unlike the tricyclics and like SSRIs, they are not active at histaminergic, muscarinic, or alpha (1)-adrenergic receptors.

Dosage & Administration

Initial Treatment: The recommended starting dose for venlafaxine/Effexor tablets is 75 mg/day, administered in two or three divided doses, taken with food. Depending on tolerability and the need for further clinical effect, the dose may be increased to 150 mg/day.

Dosage for Elderly Patients: No dose adjustment is recommended for elderly patients on the basis of age. As with any antidepressant, however, caution should be exercised in treating the elderly. When individualizing the dosage, extra care should be taken when increasing the dose.

Maintenance Treatment: It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacological therapy beyond response to the acute episode.

weeks of maintenance treatment as they had received during the acute stabilization phase, longer-term efficacy was demonstrated. A second longer-term study has demonstrated the efficacy of venlafaxine/Effexor tablets in maintaining an antidepressant response in patients with recurrent depression

Discontinuing Venlafaxine Tablet: Symptoms associated with discontinuation of venlafaxine/Effexor tablets, other SNRIs, and SSRIs, have been reported. Patients should be monitored for these symptoms when discontinuing treatment.

Interaction

Increased risk of serotonin syndrome with TCA, SSRI, SNRI, lithium, sibutramine, tramadol. May increase serum levels with CYP3A4 inhibitors (e.g. ketoconazole, atazanavir, clarithromycin). May increase serum levels of haloperidol. May decrease serum levels of indinavir. May increase bleeding risk with aspirin, NSAIDs, warfarin and other anticoagulants.

Contraindications

Concomitant use with MAOIs or within 14 days of discontinuing the MAOI. Use with linezolid or IV methylene blue.

Side Effects

Changes in behaviour, suicidal ideation, agitation, tremor, nervousness, anxiety, insomnia, confusions, abnormal dreams, HTN, nausea, headache, asthenia, somnolence, dizziness, dry mouth, vomiting, constipation, diarrhoea, dyspepsia,

abdominal pain, anorexia, sexual dysfunction, urinary frequency, visual disturbances, mydriasis, vasodilatation, paraesthesia, hypertonia, chills or fever, palpitations, wt gain or loss, arthralgia, myalgia, tinnitus, pruritus, dyspnoea, yawning, rashes, sweating.

Pregnancy & Lactation

Neonates exposed to venlafaxine/Effexor tablets, USP, other SNRIs, or SSRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.

When treating pregnant women with venlafaxine/Effexor tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.

Precautions & Warnings

History of MI or unstable cardiac disease, seizure; hypomania or mania, increased intraocular pressure or at risk of acute narrow-angle glaucoma, at risk of bleeding. Renal and hepatic impairment. Gradual dose reduction is recommended rather than abrupt withdrawal. Pregnancy and lactation.

Use in Special Populations

Dosage For Patients With Hepatic Impairment: Given the decrease in clearance and increase in elimination half-life for both venlafaxine and ODV that is observed in patients with

hepatic cirrhosis and mild and moderate hepatic impairment compared to normal subjects; it is recommended that the total daily dose be reduced by 50% in patients with mild to moderate hepatic impairment.

Dosage For Patients With Renal Impairment: Given the decrease in clearance for venlafaxine/Effexor and the increase in elimination half-life for both venlafaxine and ODV that is observed in patients with renal impairment (GFR = 10 to 70 mL/min)

compared to normal, it is recommended that the total daily dose be reduced by 25% in patients with mild to moderate renal impairment.

Overdose Effects

Symptoms: Sweating, dizziness, somnolence, mydriasis, convulsions, vomiting, ECG changes, cardiac arrhythmias and seizures.

Management: Symptomatic and supportive treatment. Ensure adequate airway, oxygenation and ventilation. Initiate gastric lavage immediately after ingestion. Admin activated charcoal to reduce absorption. Monitor cardiac rhythm and vital signs.

Storage Conditions

Store between 20-25° C.